# Edwards EVOQUE Eos MISCEND Study

Study · id `cardio:ct-nct02718001` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02718001](<https://clinicaltrials.gov/study/NCT02718001>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02718001

Browse, organ or system: Heart  
Browse, condition area: Heart failure; Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 123 participants.

## Technical summary

Registry record NCT02718001. Allocation not applicable; no masking; primary purpose treatment. Start 2015-02-06 (actual); primary completion 2028-04-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 123 participants (planned count; ClinicalTrials.gov record NCT02718001, source copy `cardio:ctgov-nct02718001-2026-04-13`, retrieved 2026-10-26)
- Started: 2015-02-06 (actual) (ClinicalTrials.gov record NCT02718001, source copy `cardio:ctgov-nct02718001-2026-04-13`, retrieved 2026-10-26)
- Primary completion: 2028-04-30 (anticipated) (ClinicalTrials.gov record NCT02718001, source copy `cardio:ctgov-nct02718001-2026-04-13`, retrieved 2026-10-26)
- Completion: 2033-04-30 (anticipated) (ClinicalTrials.gov record NCT02718001, source copy `cardio:ctgov-nct02718001-2026-04-13`, retrieved 2026-10-26)
- Countries: United States; Canada (ClinicalTrials.gov record NCT02718001, source copy `cardio:ctgov-nct02718001-2026-04-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02718001-2026-04-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Edwards EVOQUE Eos MISCEND Study
- Condition: Mitral Valve Regurgitation (Degenerative or Functional)
- Intervention (Device): Edwards EVOQUE Eos Mitral Valve Replacement System
- Lead sponsor: Edwards Lifesciences
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Mitral regurgitation (`cardio:mitral-regurgitation`)
- Registry lists this organization as the lead sponsor: Edwards Lifesciences (`cardio:edwards-lifesciences`)

## Provenance

Content hash: cf915dd3006048866f74a23685fc4a15c2b0bf8c58dccdefc547bf8d825f76a9
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
